NCT05809648
A Study to Assess the Accuracy of Magnetocardiography (MCG) to Diagnose True Ischemia in Patients With Chest Pain in the ED
Enrolling by Invitation
Not specifiedAges 18+ObservationalMayo ClinicInvestigator-initiated
~1,000 participants
Updated 2026-01-13 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnostic Accuracy
Measured over 12 months
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Sara Hevesi, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients presenting to the ED with acute chest pain when an ACS is on the differential diagnosis.
Patient willing and able to give informed consent.
Exclusion
ST elevation \> 1 mm on any two contiguous ECG leads.
Hemodynamic instability (SBP \>220 or \<80, HR \>160).
Pregnant patients.
Incarcerated patients (FMC patients).
Patients with a pacemaker or defibrillator.
Metal implants in the body (that are not MRI safe).
Patients that are unable to lie down in the MCG machine or stay still.
Patients who are unable to understand the informed consent process (ex: non-English speakers without an available interpreter, cognitive delay).
Patients without the capacity to provide written informed consent
What this trial measures
- Diagnostic Accuracy12 months
Our primary objective is to measure the diagnostic accuracy of the Mesuron Avalon-H90 MCG device to detect ACS (unstable angina, NSTEMI) in Emergency Department patients who present with acute chest pain when compared to the current goal standard.